AZN - AstraZeneca Stock Tumbles After Q4 Performance - Here's Why | Benzinga
AstraZeneca Plc (NASDAQ:AZN) reported fourth-quarter 2023 sales of $12.02 billion, up 7% Y/Y (+8% at constant currency), slightly below the consensus of $12.09 billion, fueled by strong global demand growth for cancer drugs.
Excluding COVID-19 medicines, fourth quarter 2023 revenue increased by 16% to $12.04 billion.
The company reported a core EPS of $1.45, up 5% (+7% on constant currency), with earnings per ADS reached $0.72, missing the consensus of $0.79.
Also Read: AstraZeneca Tries To Reach New Ground For Its Lead Cancer Drug Imfinzi With New Data In Liver Cancer Study.
Citing some analysts, the Wall Street Journal noted that AstraZeneca shares ...